New evidences for C-reactive protein (CRP) deposits in the arterial intima as a cardiovascular risk factor

Clinical Interventions in Aging

Volumn 3, Issue 2, 2008, Pages 341-349

  Montecucco, Fabrizio ^a   Mach, François ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Atherosclerosis; C reative protein; Cardiovascular risk; Inflammation; Plaque

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; CLOPIDOGREL; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; DIET SUPPLEMENTATION; DRUG MECHANISM; HUMAN; HYPERLIPIDEMIA; IMMUNE RESPONSE; INFLAMMATION; ISCHEMIC HEART DISEASE; NONHUMAN; PATHOGENESIS; PHYSICAL ACTIVITY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING CESSATION; WEIGHT REDUCTION;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; HUMANS; INFLAMMATION; RISK FACTORS; TUNICA INTIMA;

EID: 47849107901     PISSN: 11769092     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (140)

1. Abramson JL, Vaccarino V. 2002. Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. Arch Intern Med, 162:1286-92.
2. Albert CM, Ma J, Rifai N, et al. 2002. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation, 105:2595-9.
3. Albert MA, Glynn RJ, Ridker PM. 2003. Alcohol consumption and plama concentration of C-reactive protein. Circulation, 107:443-7.
4. Ansell BJ, Watson KE, Weiss RE, et al. 2003. hsCRP and HDL Effects Statin Trial (CHEST): rapid of effect of statin therapy on C-reactive protein and high-density lipoprotein levels. A clinical investigation. Heart Dis, 5:2-7.
5. Arnaud C, Burger F, Steffens S, et al. 2005. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol, 25:1231-6.
6. Asgary S, Moshtaghian J, Naderi G, et al. 2007. Effects of dietary red clover on blood factors and cardiovascular fatty streak formation in hypercholesterolemic rabbits. Phytother Res, 21:768-70.
7. Aukrust P, Berge RK, Ueland T, et al. 2001. Interaction between chemokines and oxidative stress: possible pathogenetic role in acute coronary syndromes. J Am Coll Cardiol, 37:485-91.
8. Backes JM, Howard PA, Moriarty PM. 2004. Role of C-reactive protein in cardiovascular disease. Ann Pharmacother, 38:110-18.
9. Balistreri CR, Vasto S, Listi F, et al. 2006. Association between + 1059G/C CRP polymorphism and acute myocardial infarction in a cohort of patients from Sicily: a pilot study. Ann N Y Acad Sci, 1067:276-81.
10. Ballou SP, Lozanski G. 1992. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine, 4:361-8.
11. Bastard JP, Maachi M, Lagathu C, et al. 2006. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw, 17:4-12.
12. Bazzano LA, He J, Muntner P, et al. 2003. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med, 138:891-7.
13. Ben-Yehuda O. 2007. High-sensitivity C-reactive protein in every chart? The use of biomarkers in individual patients. J Am Coll Cardiol, 49:2139-41.
14. Bermudez EA, Rifai N, Buring JE, et al. 2002. Relation between markers of systemic vascular inflammation and smoking in women. Am J Cardiol, 89:1117-19.
15. Biomarkers Definitions Working Group. 2001. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther, 69:89-95.
16. Blake GJ, Ridker PM. 2002. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med, 252:283-94.
17. Boekholdt SM, Hack CE, Sandhu MS, et al. 2006. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis, 187:415-22.
18. Calabró P, Willerson JT, Yeh ET. 2003. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation, 108:1930-2.
19. Cao H, Hegele RA. 2000. Human C-reactive protein (CRP) 1059G/C polymorphism. J Hum Genet, 45:100-1.
20. Carter AM. 2005. Inflammation, thrombosis and acute coronary syndromes. Inflammation, thrombosis and acute coronary syndromes. Diab Vasc Dis Res, 2:113-21.
21. Cesari M, Penninx BW, Newman AB, et al. 2003. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation, 108:2317-22.
22. Chang MK, Binder CJ, Torzewski M, et al. 2002. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA, 99:13043-8.
23. Chasman DI, Kozlowski P, Zee RY, et al. 2006. Qualitative and quantitive effects of APOE genetic variation on plasma C-reactive protein, LDL-cholesterol, and apoE protein. Genes Immun, 7:211-19.
24. Chew DP, Bhatt DL, Robbins MA, et al. 2001. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol, 88:672-4.
25. Church TS, Barlow CE, Earnest CP, et al. 2002. Associations between cardiorespiratory fitness and C-reactive protein in men. Arterioscler Thromb Vasc Biol, 22:1869-76.
26. Danenberg HD, Kantak N, Grad E, et al. 2007. C-reactive protein promotes monocyte-platelet aggregation: an additional link to the inflammatory-thrombotic intricacy. Eur J Haematol, 78:246-52.
27. Danesh J, Collins R, Appleby P, et al. 1998. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA, 279:1477-82.
28. Danesh J, Whincup P, Walker M, et al. 2000. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ, 321:199-204.
29. Danesh J, Wheeler JG, Hirschfield GM, et al. 2004. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med, 350:1387-97.
30. Després JP, Lemieux I, Pascot A, et al. 2003. Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome. Arterioscler Thromb Vasc Biol, 23:702-3.
31. Devaraj S, Xu DY, Jialal I. 2003. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation, 107:398-404.
32. Domínguez-Muñoz JE, Malfertheiner P. 1993. Management of severe acute pancreatitis. Gastroenterologist, 1:248-56.
33. Dong Q, Wright JR. 1996. Expression of C-reactive protein by alveolar macrophages. J Immunol, 156:4815-20.
34. Du Clos TW. 2000. Function of C-reactive protein. Ann Med, 32:274-8.
35. Du Clos TW, Mold C. 2004. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res, 30:261-77.
36. Eklund C, Jahan F, Pessi T, et al. 2003. Interleukin 1B gene polymorphim is associated with baseline C-reactive protein levels in healthy individuals. Eur Cytokine Netw, 14:168-71.
37. Eklund C, Kivimaki M, Islam MS, et al. 2007. C-reactive protein genetics is associated with carotid artery compliance in men in The Cardiovasculat Rik in Young Finns Study. Atherosclerosis, 196:841-8.
38. Esposito K, Pontillo A, Di Palo C, et al. 2003. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA, 289:1799-804.
39. Feldman M, Jialal I, Devaraj S, et al. 2001. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol, 37:2036-41.
40. Ford ES. 2002. Does Exercise reduce inflammation? Physical activity and C-reactive protein among U.S. adults. Epidemiology, 13:561-8.
41. Ford ES, Giles WH, Myers GL, et al. 2003. C-reactive protein concentration distribution among US children and young adults: findings from the National Health and Nutrition Examination Survey, 1999-2000. Clin Chem, 49:1353-7.
42. Ford ES, Liu S, Mannino DM, et al. 2003. C-reactive protein concentrations of blood vitamins, carotenoids, and selenium among United States adults. Eur J Clin Nutr, 57:1157-63.
43. Fuchs CS, Stampfer MJ, Colditz GA, et al. 1995. Alcohol consumption and mortality among women. N Engl J Med, 332:1245-50.
44. Geffken DF, Cushman M, Burke GL, et al. 2001. Association between physical activity and markers of inflammation in a healthy elderly population. Am J Epidemiol, 153:242-50.
45. Grundy SM, Vega GL, McGovern ME, et al. 2002. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med, 162:1568-76.
46. Gussekloo J, Schaap MC, Frölich M, et al. 2000. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler Thromb Vasc Biol, 20:1047-51.
47. Haffner SM, Greenberg AS, Weston WM, et al. 2002. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation, 106:679-84.
48. Han KH, Hong KH, Park JH, et al. 2004. C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation, 109:2566-71.
49. Hansson GK, Libby P, Schöenbeck U, et al. 2002. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res, 91:281-91.
50. Hansson GK, Libby P. 2006. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol, 6:508-19.
51. Ikonomidis I, Andreotti F, Economou E, et al. 1999. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation, 100:793-8.
52. Ikuta T, Okubo H, Ishibashi H, et al. 1986. Human lymphocytes synthesize C-reactive protein. Inflammation, 10:223-32.
53. Inoue T, Kato T, Uchida T, et al. 2005. Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting. J Am Coll Cardiol, 46:239-45.
54. Jakimiuk AJ, Bogusiewics M, Skorupski P, et al. 2007. Relationship between estrogen receptor-alpha polymorphism and serum levels of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, C-reactive protein and homocysteine in postmenopausal women. Gynecol Endocrinol, 23:584-9.
55. Jialal I, Devaraj S, Venugopal SK. 2004. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension, 44:6-11.
56. Jiang S, Xia D, Samols D. 2006. Expression of rabbit C-reactive protein in transgenic mice inhibits development of antigen-induced arthritis. Scand J Rheumatol, 35:351-5.
57. Johnson RC, Chapman SM, Dong ZM, et al. 1997. Absence of P-selectin dalays fatty streak formation in mice. J Clin Invest, 99:1037-43.
58. Kashyap ML, McGovern ME, Berra K, et al. 2002. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol, 89:672-8.
59. Kathiresan S, Larson MG, Vasan RS, et al. 2006. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to inteindividual variability in serum C-reactive protein level. Circulation, 113:1415-23.
60. Koenig W. 2005. Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein. Int J Cardiol, 98:199-206.
61. Kolb-Bachofen V, Puchta-Teudt N, Egenhofer C. 1995. Expression of membrane-associated C-reactive protein by human monocytes: indications for a selectin-like activity participating in adhesion. Glycoconj J, 12:122-7.
62. Kopp HP, Kopp CW, Festa A, et al. 2003. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol, 23:1042-7.
63. Kovacs A, Green F, Hansson LO, et al. 2005. A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein. Atherosclerosis, 178:193-8.
64. Kota AE, Baum LL. 1986. C-reactive protein is produced by a small number of normal human peripheral blood lymphocytes. J Exp Med, 164:321-6.
65. Lagrand WK, Visser CA, Hermens WT, et al. 1999. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation, 100:96-102.
66. Lakka HM, Lakka TA, Rankinen T, et al. 2006. The TNF-alpha G-308A polymorphism is associated with C-reactive protein levels: the HERITAGE Family Study. Vascul Pharmacol, 44:377-83.
67. LaMonte MJ, Durstine JL, Yanowitz FG, et al. 2002. Cardiorespiratory fitness and C-reactive protein among a tri-ethnic sample of women. Circulation, 106:403-6.
68. Libby P, Ridker PM. 2004. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med, 116(Suppl 6A):9S-16S.
69. Lincoff AM, Kereiakes DJ, Mascelli MA, et al. 2001. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation, 104:163-7.
70. Lipscombe LL, Gomes T, Lévesque LE, et al. 2007. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA, 298:2634-43.
71. Lowe GD, Yarnell JW, Rumley A, et al. 2001. C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell study: are inflammation and fibrin turnover linked in pathogenesis? Arterioscler Thromb Vasc Biol, 21:603-10.
72. Mahmoud FA, Rivera NI. 2002. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep, 4:250-5.
73. Mancia G, De Backer G, Dominiczak A, et al. 2007.2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J, 28:1462-536.
74. Melenovsky V, Malik J, Wichterle D, et al. 2002. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am Heart J, 144:E6.
75. Mendall MA, Strachan DP, Butland BK, et al. 2000. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J, 21:1584-90.
76. Miller DT, Zee RY, Suk Danik J, et al. 2005. Association of common CRP gene variants with CRP levels and cardiovascular events. Ann Hum Genet, 69:623-38.
77. Mori S, Nakata Y, Endo H. 1991. Involvements of fibronectin and lysophosphatidylcholine for selective binding of C-reactive protein. Cell Mol Biol, 37:421-31.
78. Mortensen RF, Zhong W. 2000. Regulation of phagocytic leukocyte activities by C-reactive protein. J Leukoc Biol, 67:495-500.
79. Nabata A, Kuroki M, Ueba H, et al. 2007. C-reactive protein induces endothelial cell apoptosis and matrix metalloproteinase-9 production in human mononuclear cells: implication for the destabilization of atherosclerotic plaque. Atherosclerosis, [Epub ahead of print].
80. Nerurkar SS, McDevitt PJ, Scott GF, et al. 2005. Lipopolysaccharide (LPS) contamination plays the real role in C-reactive protein-induced IL-6 secretion from human endothelial cells in vitro. Arterioscler Thromb Vosc Biol, 24:e136.
81. Nissen SE, Wolski K. 2007. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med, 356:2457-71.
82. Osawa H, Tabara Y, Kawamoto R, et al. 2007. Plasma resistin, associated with single nucleotide polymorphism -420, is correlated with insulin resistance, lower HDL cholesterol, and high-sensitivity C-reactive protein in the Japanese general population. Diabetes Care, 30:1501-6.
83. Pai JK, Mukamal KJ, Rexrode KM, et al. 2008. C-reactive protein (CRP) gene polymorphisms, CRP levels, and risk of incident coronary heart disease in two nested Case-Control Study. PLoS ONE, 3:e1395.
84. Park R, Detrano R, Xiang M, et al. 2002. Combined use of computed tomography coronary calcium scores and C-reactive protein levels in predicting cardiovascular events in nondiabetic individuals. Circulation, 106:2073-7.
85. Pasceri V, Willerson JT, Yeh ET. 2000. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation, 102:2165-8.
86. Paul A, Ko KW, Li L, et al. 2004. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation, 109:647-55.
87. Pearson TA, Mensah GA, Alexander RW, et al. 2003. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107:499-511.
88. Pepys MB, Hirschfield GM. 2003. C-reactive protein: a critical update. J Clin Invest, 111: 1805-12.
89. Pepys MB, Hawkins PN, Kahan MC, et al. 2005. Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res, 97:e97-e103.
90. Pischon T, Hankinson SE, Hotamisligil GS, et al. 2003. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation, 108:155-60.
91. Reuben DB, Judd-Hamilton L, Harris TB, et al. 2003. The associations between physical activity and inflammatory markers in high-functioning older persons: MacArthur Studies of Successful Aging. J Am Geriatr Soc, 51:1125-30.
92. Ridker PM, Cushman M, Stampfer MJ, et al. 1997. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med, 336:973-9.
93. Ridker PM, Buring JE, Shih J, et al. 1998. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation, 98:731-3.
94. Ridker PM, Cushman M, Stampfer MJ, et al. 1998. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation, 97:425-8.
95. Ridker PM, Rifai N, Pfeffer MA, et al. 1999. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 100:230-5.
96. Ridker PM, Hennekens CH, Buring JE, et al. 2000. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med, 342:836-43.
97. Ridker PM, Rifai N, Pfeffer M, et al. 2000. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation, 101:2149-53.
98. Ridker PM, Rifai N, Clearfield M, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. 2001. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med, 344:1959-65.
99. Ridker PM, Stampfer MJ, Rifai N. 2001. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA, 285:2481-5.
100. Ridker PM, Rifai N, Rose L, et al. 2002. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med, 347:1557-65.
101. Ridker PM, Fonseca FA, Genest J, et al. 2007. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol, 100:1659-64.
102. Roivainen M, Viik-Kajander M, Palosuo T, et al. 2000. Infections, inflammation, and the risk of coronary heart disease. Circulation, 101:252-7.
103. Root M, Cobb F. 2004. Traditional risk factors for coronary heart disease. JAMA, 291:299.
104. Rowe IF, Soutar AK, Trayner IM, et al. 1984. Circulating human C-reactive protein binds very low density lipoproteins. Clin Exp Immunol, 58:237-44.
105. Russell AI, Cunninghame Graham DS, Shepherd C, et al. 2004. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet, 13:137-47.
106. Rydén L, Standl E, Bartnik M, et al. 2007. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Forse on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J, 28:88-136.
107. Shin KK, Jang Y, Koh SJ, et al. 2007. Influence of the IL-6-572>G polymorphism on inflammatory markers according to cigarettes smoking in Korean healthy men. Cytokine, 39:116-22.
108. Singh P, Hoffmann M, Wolk R, et al. 2007. Leptin induces C-reactive protein expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol, 27:e302-7.
109. Staels B, Koenig W, Habib A, et al. 1998. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature, 393:790-3.
110. Sun H, Koike T, Ichikawa T, et al. 2005. C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am J Pathol, 167:1139-48.
111. Sykora J, Subrt I, Didek P, et al. 2006. Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G --> A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease. J Pediatr Gastroenterol Nutr, 42:479-87.
112. Szalai AJ, McCrory MA, Cooper GS, et al. 2002. Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun, 3:14-19.
113. Szalai AJ, Wu J, Lange EM, et al. 2005. Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. J Mol Med, 83:440-7.
114. Tall AR. 2004. C-reactive protein reassessed. N Engl J Med, 350:1450-2.
115. Tang NP, Wang LS, Yang L, et al. 2007. A polymorphism in the resistin gene promoter is related to increased C-reactive protein levels in patients with coronary artery disease. Clin Chem Lab Med, 45:1471-5.
116. Taylor KE, Giddins JC, Van den Berg CW. 2005. C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol, 25:1225-30.
117. Tchernof A, Nolan A, Sites CK, et al. 2002. Weight loss reduces C-reactive protein level in obese postmenopausal women. Circulation, 105:564-9.
118. Thompson D, Pepys MB, Wood SP. 1999. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure, 7:169-77.
119. Tillet WS, Francis T. 1930. Serological reactions in pneumonia with a non-protein somatic fraction of the Pneumococcus. J Exp Med, 52:561-71.
120. Torzewski M, Rist C, Mortensen RF, et al. 2000. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol, 20:2094-9.
121. Van den Berg CW, Taylor KE, Lang D. 2004. C-reactive protein-induced in vitro vasorelaxation is an artefact caused by the presence of sodium azide in commercial preparations. Arterioscler Thromb Vasc Biol, 24: e168-71.
122. Van der Vusse GJ, van Bilsen M, Reneman RS. 1994. Ischemia and reperfusion induces alterations in membrane phospholipids: an overview. Ann N Y Acad Sci, 723:1-14.
123. Vasan RS, Sullivan LM, Roubenoff R, et al. 2003. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation, 107:1486-91.
124. Venugopal SK, Devaraj S, Yuhanna I, et al. 2002. Demostration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation, 106:1439-41.
125. Venugopal SK, Devaraj S, Jialal I. 2003. C-reactive protein decreases prostacyclin release from from human aortic endothelial cells. Circulation, 108:1676-8.
126. Verma S, Li SH, Badiwala MV, Weisel RD, et al. 2002. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation, 105:1890-6.
127. Verma S, Wang CH, Li Sh, et al. 2002. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation, 106:913-19.
128. Vermeire S, Van Assche G, Rutgeerts P. 2004. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis, 10:661-5.
129. Walston JD, Fallin MD, Cushman M, et al. 2007. Il-6 gene variation is associated with IL-6 and C-reactive protein levels but not cardiovascular outcomes in the Cardiovascular Healthy Study. Hum Genet, 122:485-94.
130. Wang CH, Li SH, Weisel RD, et al. 2003. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation, 107:1783-90.
131. Wannamethee SG, Lowe GD, Whincup, PH, et al. 2002. Physical activity and hemostaic and inflammatory variables in elderly men. Circulation, 105:1785-90.
132. Williams TN, Zhang CX, Game BA, et al. 2004. C-reactive protein stimulates MMP-1 expression in U937 histiocytes through Fc[gamma]RII and extracellular signal-regulated kinase pathways: an implication of CRP involvement in plaque destabilization. Arterioscler Thromb Vasc Biol, 24:61-6.
133. Wong LY, Leung RY, Ong KL, Cheung BM. 2007. Plasma levels of fibrinogen and C-reactive protein are regulated to interleukin-6 gene -572C > 6 polymorphism in subjects with and without hypertension. J Hum Hypertens, 21:875-82.
134. Woollard KJ, Phillips DC, Griffiths HR. 2002. Direct modulatory effect of C-reactive protein on primary human monocytes adhesion to human endothelial cells. Clin Exp Immunol, 130:256-62.
135. Worthley SG, Osende JI, Helft G, et al. 2001. Coronary artery disease: pathogenesis and acute coronary syndromes. Mt Sinai J Med, 68:167-81.
136. Xia D, Samols D. 1997. Transgenic mice expressing rabbit C-reactive protein are resistant to endotoxiemia. Proc Natl Acad Sci U.S.A., 94:2575-80.
137. Zhang R, Becnel L, Li M, et al. 2006. C-reactive protein impairs human CD14+ monocyte-derived dendritic cell differentiation, maturation and function. Eur J Immunol, 36:2993-3006.
138. Zhang D, Che D, Zhao S, Sun Y. 2007. Effects of atorvastatin on C-reactive protein secretions by adipocytes in hypercholesterolemic rabbits. J Cardiovasc Pharmacol, 50:281-5.
139. Zhang YY, Gottardo L, Mlynarski W, et al. 2007. Genetic variability at the leptin receptor (LEPR) locus is a determinant of plasma fibrinogen and C-reactive protein levels. Atherosclerosis, 191:121-7.
140. Zhong W, Zen Q, Tebo J, et al. 1998. Effect of human C-reactive protein on chemokine and chemotactic factor-induced neutrophil chemotaxis and signaling. J Immunol, 161:2533-40.